Replimune (REPL) stock plummets as report suggests FDA’s top regulator of cancer drugs intervened in rejecting its lead asset. Read more here.

Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in refractory melanoma. Click to read.

ATLANTA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit ...

NEW YORK, Aug. 9, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 ...

RADNOR, Pa., Aug. 15, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against ...

NEW YORK - August 5, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit ...

“ Nobody 2 ” picked up $1.3 million in preview screenings on Thursday as the action sequel heads into an opening weekend that will see it face off against “Weapons.” The film, which brings ...

NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such ...

The Vibe-Coding Companies and Founders to Watch in 2025 From Anthropic to Replit, these are the key vibe-coding players to follow.